Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Financial Results:
Wockhardt Ltd reported Revenues for Q2FY24 of ₹753.00 Crores up from ₹679.00 Crore year on year, a rise of 10.9%.
Total Expenses for Q2FY24 of ₹812.00 Crores up from ₹771.00 Crores year on year, a rise of 5.32%.
Consolidated Net Profit of -₹73.00 Crores from -₹207.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹5.34, from -₹13.12 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.